Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Drug Profile

Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Alternative Names: AR 201- Aimmune Therapeutics; AR 301- Aimmune Therapeutics; AR201; AR301; Food allergy OIT - Aimmune Therapeutics; Food allergy oral immunotherapies - Aimmune Therapeutics

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aimmune Therapeutics
  • Class Allergens; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Food hypersensitivity

Most Recent Events

  • 12 Mar 2018 Aimmune Therapeutics intends to file an IND application with the US FDA for AR 201 for food allergy (egg allergy) in the year end of 2018
  • 12 Mar 2018 Aimmune Therapeutics intends to file an IND application with the US FDA for AR 301 for food allergy (walnut allergy) in second half of 2019
  • 12 Mar 2018 Aimmune Therapeutics plans a phase II trial for AR 201 Food allergy (egg allergy) in first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top